scispace - formally typeset
G

Guido Kroemer

Researcher at Institut Gustave Roussy

Publications -  1546
Citations -  294816

Guido Kroemer is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Programmed cell death & Apoptosis. The author has an hindex of 236, co-authored 1404 publications receiving 246571 citations. Previous affiliations of Guido Kroemer include Karolinska Institutet & Spanish National Research Council.

Papers
More filters
Journal Article

Effects of Mycoplasma fermentans on the myelomonocytic lineage. Different molecular entities with cytokine-inducing and cytocidal potential.

TL;DR: It is shown that M. fermentans affects the function of human monocytes and myelomonocytic cell lines on at least two different levels and that certain AIDS-associated mycoplasma species perturb the function and/or generation of cells from the myelmonocytic lineage via several distinct pathways.
Journal ArticleDOI

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

TL;DR: The Cancer Immunotherapy Trials Network investigators review the immunodynamic effects of specific classes of immunotherapeutic agents to focus immune assessment modalities and sites, both systemic and importantly intratumoral, which are critical to the success of the rapidly growing field of immuno-oncology.
Book ChapterDOI

Chapter 8 Measurement of membrane permeability and permeability transition of mitochondria

TL;DR: Experimental procedures designed to measure apoptosis associated mitochondrial membrane permeabilization, both in intact cells and in isolated mitochondria are presented, suggesting that opening of the PT pore can be rate limiting for the death process.
Journal ArticleDOI

Immunogenic cell death inducers as anticancer agents.

TL;DR: The capacity of candidate ICD inducers to kill mouse cancer cell lines in vitro so that the resulting dead-cell preparation would elicit protective anticancer immune responses upon its subcutaneous injection into immunocompetent, syngenic mice was validated.